Rahul Singhvi, Resilience CEO

Re­silience col­lab­o­rates with the Mayo Clin­ic to man­u­fac­ture rare and com­plex dis­ease drugs

Af­ter net­ting its Se­ries D round of fund­ing in June, Re­silience is not sit­ting around and rest­ing on its lau­rels.

The Bob Nelsen-backed con­tract man­u­fac­tur­er on Mon­day an­nounced a new strate­gic col­lab­o­ra­tion with the Mayo Clin­ic. The re­la­tion­ship is cen­tered around man­u­fac­tur­ing bio­ther­a­peu­tics for rare and com­plex con­di­tions, with the fo­cus on bi­o­log­ics in­clud­ing those based in cells, blood, en­zymes, tis­sues, genes or ge­net­i­cal­ly en­gi­neered cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.